These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38672120)

  • 1. Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
    Guo Z; Yu J; Chen Z; Chen S; Wang L
    Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps.
    Gitto S; Natalini A; Antonangeli F; Di Rosa F
    Front Immunol; 2021; 12():755304. PubMed ID: 34867987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
    Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
    Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
    Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
    Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
    Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
    Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.
    Budimir N; Thomas GD; Dolina JS; Salek-Ardakani S
    Cancer Immunol Res; 2022 Feb; 10(2):146-153. PubMed ID: 34937730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
    Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma.
    Zeng Q; Yang J; Ji J; Wang P; Zhang L; Yan G; Wu Y; Chen Q; Liu J; Zhang G; Wang X
    Oncoimmunology; 2022; 11(1):2061396. PubMed ID: 35402079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors.
    Li J; Yan Y; Zhang P; Ding J; Huang Y; Jin Y; Li L
    J Control Release; 2022 Nov; 351():231-244. PubMed ID: 36122899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.
    Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade.
    Oh KY; Hong SD; Yoon HJ
    J Oral Pathol Med; 2024 Mar; 53(3):217-225. PubMed ID: 38449350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.
    Tong Q; Xu J; Wu A; Zhang C; Yang A; Zhang S; Lin H; Lu W
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of immune checkpoint blockade in breast cancer.
    Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
    Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tumor cell pyroptosis in anti-tumor immunotherapy.
    Zhang L; Bai H; Zhou J; Ye L; Gao L
    Cell Insight; 2024 Jun; 3(3):100153. PubMed ID: 38464416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.